Candel Therapeutics Confirms Emerging Growth Status in 8-K Filing

TL;DR

**Candel Therapeutics is still an emerging growth company, meaning less red tape but potentially higher risk.**

AI Summary

Candel Therapeutics, Inc. filed an 8-K on January 3, 2024, reporting an "Other Event" that occurred on December 28, 2023. This filing indicates that the company is an "emerging growth company" as defined by the SEC, which means it benefits from reduced reporting requirements. For investors, this matters because it signals that Candel Therapeutics is still in a relatively early stage of its public company lifecycle, potentially implying higher growth potential but also higher risk due to less stringent oversight and disclosure compared to larger, more established companies.

Why It Matters

This filing confirms Candel Therapeutics' status as an emerging growth company, which impacts its regulatory obligations and provides insights into its stage of development as a public entity.

Risk Assessment

Risk Level: medium — Emerging growth company status can mean less public information is available, increasing investment risk due to reduced transparency.

Analyst Insight

An investor should understand that Candel Therapeutics' emerging growth company status means it may have fewer public disclosures than larger companies, requiring more independent research to assess its financial health and prospects.

Key Numbers

• 20231228 — Conformed Period of Report (The date of the event being reported in the 8-K.)
• 001-40629 — SEC File Number (Unique identifier for the company's filings with the SEC.)

Key Players & Entities

• Candel Therapeutics, Inc. (company) — the registrant filing the 8-K
• December 28, 2023 (date) — date of the earliest event reported
• January 3, 2024 (date) — date the 8-K was filed
• 001-40629 (dollar_amount) — Commission File Number
• CADL (company) — trading symbol for Common Stock

FAQ

Key Financial Figures

• $0.01 — nge on which registered Common Stock, $0.01 par value per share CADL The Nasdaq
• $1.00 — mpany’s common stock close above $1.00 per share pursuant to Nasdaq Listing Ru

Filing Documents

• cadl-20231228.htm (8-K) — 40KB
• 0000950170-24-000539.txt ( ) — 160KB
• cadl-20231228.xsd (EX-101.SCH) — 2KB
• cadl-20231228_lab.xml (EX-101.LAB) — 16KB
• cadl-20231228_pre.xml (EX-101.PRE) — 11KB
• cadl-20231228_htm.xml (XML) — 5KB

01 Other Events

Item 8.01 Other Events. As previously disclosed, on November 15, 2023, Candel Therapeutics, Inc. (the “Company”) received a letter from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it was not in compliance with the requirement that the bid price for the Company’s common stock close above $1.00 per share pursuant to Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Requirement”) because the price of the Company’s common stock had closed below $1.00 per share for 30 consecutive business days, and that the Company had 180 days to regain compliance with the Minimum Bid Requirement. On December 28, 2023, the Staff notified the Company that, as of December 28, 2023, the Company had regained compliance with the Minimum Bid Requirement and that the matter is now closed.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Candel Therapeutics, Inc. Date: January 3, 2024 By: /s/ Paul Peter Tak Paul Peter Tak, M.D., Ph.D., FMedSci President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR